ABBV-CLS-579 + pembrolizumab

ABBV-CLS-579 + pembrolizumab is an investigational combination therapy for advanced or metastatic solid tumors. ABBV-CLS-579 is a small molecule inhibitor targeting tyrosine-protein phosphatase non-receptor type 1 and 2 (PTPN1 and PTPN2), which are negative regulators of immune signaling pathways. By inhibiting these phosphatases, ABBV-CLS-579 aims to enhance anti-tumor immune responses. Pembrolizumab is a monoclonal antibody that targets programmed cell death protein 1 (PD‑1), acting as an immune checkpoint inhibitor to promote T-cell mediated anti-tumor activity. The combination seeks to synergistically boost the immune system's ability to recognize and destroy cancer cells by both removing inhibitory signals (via PD‑1 blockade) and enhancing pro-inflammatory signaling (via PTPN1/PTPN2 inhibition). This regimen is being evaluated in phase 1 clinical trials for safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with locally advanced or metastatic solid tumors who have exhausted standard therapies[3][5][6][7].

Other names

ABBV CLS 579ABBVCLS-579ABBVCLS579ABBVCLS 579